株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の糖尿病治療薬市場(2017年まで):より良い血糖管理と潜在的低血糖リスクの軽減が、DPP-IV阻害剤とGLP-1作用薬の市場シェア拡大につながる

Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists

発行 GBI Research 商品コード 233227
出版日 ページ情報 英文 168 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
世界の糖尿病治療薬市場(2017年まで):より良い血糖管理と潜在的低血糖リスクの軽減が、DPP-IV阻害剤とGLP-1作用薬の市場シェア拡大につながる Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists
出版日: 2012年02月29日 ページ情報: 英文 168 Pages
概要

当レポートでは、全世界の糖尿病治療法の関連市場について分析し、最新の研究開発や、全世界および主要国の市場動向、疾患の種類(1型/2型糖尿病)別の詳細な市場構造・動向、主要企業のプロファイル、企業間提携の実体といった情報を盛り込んで、概略以下の構成でお届けします。

当レポートでは、全世界の、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • イントロダクション
  • 糖尿病市場に広がっている、3つの主なアンメットニーズ
    • 心臓病リスクのような複雑性:一部の口径薬との関係性
    • インスリン・アナログの利用患者は発癌効果が現れやすい
    • 糖尿病治療における患者コンプライアンスの低さ
  • 収益
  • 年間治療費(ACT)
  • 治療の利用パターン
  • 市場促進・抑制要因
  • ブランド/ジェネリック医薬品の市場シェア

第4章 各地域の状況

  • 米国
  • 欧州(上位5カ国)
  • 日本

第5章 個別の治療法の状況

  • 1型糖尿病の市場
  • 2型糖尿病の市場
    • イントロダクション
    • 兆候
    • 治療
    • アンメットニーズ
    • ブランド/ジェネリック医薬品の市場シェア
    • 収益
    • 年間治療費(ACT)
    • 治療の流れのアルゴリズム
    • 治療の利用パターン
    • 市場促進・抑制要因

第6章 パイプライン分析

  • イントロダクション:1型・2型糖尿病の研究開発パイプライン
  • 糖尿病治療に関する技術革新
    • 錠剤型インスリン(経口デリバリー)
    • 糖尿病性網膜症の有望な治療法
    • 糖尿病のバイオマーカー
    • 糖尿病パイプラインの重要な一部である配合剤
    • 細胞活性化療法(CAT)
  • 糖尿病におけるドラッグデリバリー(薬物送達)
    • ドラッグデリバリーの選好の決定要因
    • 現在は利用不可能な、糖尿病にとっての理想的なドラッグデリバリーの手法
    • ドラッグデリバリー・システムの技術革新
  • 有望な薬剤のプロファイル
    • rhGAD65 (Diamyd)
    • Bydureon
    • DiaPep277
    • Otelixizumab
    • Alogliptin
    • Oral-Lyn
    • Dapagliflozin
    • Canagliflozin
    • MB07803

第7章 競争環境

  • 糖尿病市場の概況
    • ヒトインスリン製品や口径薬(Actos Group(Actos and Actoplus Met)やLantusなど)が市場成長を主導する
  • 企業シェア分析:企業別(2010年、2017年)
  • 企業シェア分析:薬剤クラス別(2010年、2017年)
  • 企業のプロファイリング
    • Novo Nordisk
    • Sanofi
    • 武田薬品工業
    • Eli Lilly
    • GlaxoSmithKline (GSK)
    • Merck & Co Inc
    • Amylin Pharmaceuticals

第8章 企業合併・買収の状況

  • 概況
  • 企業合併・買収(M&A)
  • ライセンス契約
  • 共同開発

第9章 付録

図表一覧

目次
Product Code: GBIHC162MR

Summary

This report covers the key geographies of the US, the top five countries in the European region, and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of the two diabetes therapeutic indications, which are Type 1 and Type 2 diabetes. In addition, it includes market forecasts and treatment usage patterns for these two therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.

The global diabetes market is growing rapidly due to the increasing diabetes population in the developed countries of the US, the UK and Germany. In 2010, the global diabetes market was estimated at $29.3 billion, representing a compound annual growth rate (CAGR) of 10.0% between 2003 and 2010. The diabetes Type 2 market, with sales worth $21.0 billion in 2010, accounted for 72% of the total diabetes market. Insulin analogues dominated the market, followed by oral hypoglycemic agents. By 2017, the global diabetes therapeutics market is forecast to record $47.2 billion, representing a CAGR of 7.1% between 2010 and 2017. The Type 1 diabetes market is expected to account for $13.2 billion, and the Type 2 diabetes market is expected to account for $34.0 billion in 2017.

Scope

  • Data and analysis on the diabetes therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the diabetes therapeutics market from 2003 to 2010, with forecasts to 2017 for Type 1 and Type 2 diabetes.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, and treatment usage patterns such as prevalence population, treatment seeking population, diagnosed population and prescription population.
  • Key drivers and restraints that have had a significant impact on the market.
  • Market share analysis of the top companies and the drug classes in 2010 and their forecasts in 2017.
  • Competitive landscape of the global diabetes therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi, Takeda Pharmaceuticals, Eli Lilly, Merck, GlaxoSmithKline and Amylin Pharmaceuticals.

Reasons to buy

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that can fill their portfolio gaps.
  • Align the product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research “Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global diabetes therapeutics market. The report analyzes the markets for diabetes in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales and prices are forecast up to 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The Global Diabetes Therapeutics Market is Attractive despite Declining Sales of Actos and Avandia

GBI Research finds that the global diabetes therapeutics market is lucrative despite the declining sales of Actos and Avandia. The major factor driving the growth of the market is the rising prevalence rate of the diabetic population in key markets such as the US, the UK and Germany.

The global diabetes prevalence population in 2010 was estimated at 61.5 million, in which Type 1 diabetes was estimated at 7.2 million and Type 2 diabetes was estimated at 54.3 million. The Type 2 diabetes market accounted for 72% of the global diabetes therapeutics market. The diabetes market has also witnessed some product failures. Avandia (rosiglitazone), belonging to the class of thiazolidinedones, was found to increase the probability of heart risks. Following the discovery of the side effects, the sales of Avandia plunged alarmingly. The Avandia products recorded peak sales of $3 billion in 2006, falling to $572m in 2010. In addition, Actos (pioglitazone hydrochloride), another thiazolidinedone, acquired market share from Avandia, although it was also found to be associated with increasing risk of heart related complications. Nevertheless, the diabetes market still remained attractive due to increased utilization of other drugs such as insulin analogues and biguanides. At the same time, some of the promising molecules in the peptide analogues class are expected to be launched in the market.

GBI Research forecasts that the diabetes therapeutics market will grow at 7.1% between 2010 and 2017. The market will be primarily driven by the rising prevalence rates and the market entry of new products such as Teplizumab, Syncria, Alogliptin, Bydureon, Dapagliflozin, Canagliflozin, and some new molecules belonging to the peptide analogues class.

Novo Nordisk, Sanofi and Takeda Account for Nearly 60% of the Market Share in the Global Diabetes Therapeutics Market

GBI Research finds the global diabetes therapeutics market to be a concentrated market, with the top three companies (Novo Nordisk, Sanofi and Takeda) accounting for close to 60% of the total global market share in the diabetes portfolio. These three companies are the leading players in the diabetes market. The competitive landscape in the markets is set to change due to the success of recent launches of antidiabetic drugs. The market will also be impacted by the decline in sales of leading products such as GSK's Avandia and Takeda's Actos.

GBI Research estimates that the market share of Eli Lilly and Merck in the diabetes market will increase due to the potential success of Teplizumab (Eli Lilly), which is in Phase III stage of development, and Januvia (Merck), which was launched in 2006 and has increased exponentially ever since. In addition, Novo Nordisk's Victoza is expected to give tough competition to Merck's Januvia, and is expected to generate sales of $1.4 billion by 2014 for the company.

Licensing Agreement and Co-Development Strategies Would Solve the Unmet Needs of the Diabetes Market

GBI Research highlights the importance of licensing agreements and co-developments in the Type 1 and Type 2 diabetes markets. The diabetes therapeutics mergers and acquisitions (M&A) landscape will be moderately active, as only a few major pharmaceutical companies and medium size players are looking for strategic partnerships with companies that have promising drugs either in the pipeline or in the market. From 2004 until May 2011, a total of 295 deals took place in Type 1 and Type 2 diabetes, out of which licensing agreements and co-developments form the majority. The diabetes market is dominated by insulins. However, there is a need for products which are easy to administer to the patients. This unmet need and the growth potential are driving the deals activity in the industry.

Major acquisition activity that took place in 2010 includes the acquisition of OSI Pharmaceuticals by Astellas Pharma in June 2010. The acquisition considerably added to the pipeline potential of these companies in the diabetes market. Sanofi also acquired the worldwide rights from Ascendis Pharma regarding its drug delivery technology in diabetes, which allows for a drug compound to be released in the body in a precise and time-controlled fashion, creating a long-term effect. Licensing activities involving approved products such as Januvia and Galvus and Phase III products such as Oral-lyn will significantly impact the market. GBI Research suggests that licensing agreements and co-developments should continue to be an attractive strategy for players to strengthen their market positions

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Diabetes Therapeutics Market to 2017-Introduction

  • 2.1. GBI Research Report Guidance

3. Diabetes Therapeutics Market to 2017-Market Overview

  • 3.1. Introduction
  • 3.2. Three Major Unmet Needs Prevalent in the Diabetes Market
    • 3.2.1. Complications like Heart Risks are Associated with Some of the Oral Anti-Diabetic Drugs
    • 3.2.2. Patients on Insulin Analogues are Prone to Carcinogenic Effects
    • 3.2.3. Poor Patient Compliance with Anti-Diabetic Drug Therapy
  • 3.3. Revenue
  • 3.4. Annual Cost of Therapy (ACT)
  • 3.5. Treatment Usage Patterns
    • 3.5.1. Prevalence Population
    • 3.5.2. Treatment Seeking Population
    • 3.5.3. Diagnosed Population
    • 3.5.4. Prescription Population
  • 3.6. Drivers and Restraints of the Diabetes Therapeutics Market
    • 3.6.1. Drivers of the Diabetes Market
    • 3.6.2. Restraints for the Diabetes Market
  • 3.7. Branded vs. Generic Market Share in the Global Diabetes Market

4. Diabetes Therapeutics Market to 2017-Geographical Landscape

  • 4.1. The US
    • 4.1.1. Revenue
    • 4.1.2. Annual Cost of Therapy
    • 4.1.3. Treatment Usage Patterns
  • 4.2. Top Five Countries of Europe
    • 4.2.1. Revenue
    • 4.2.2. Annual Cost of Therapy
    • 4.2.3. Treatment Usage Patterns
  • 4.3. Japan
    • 4.3.1. Revenue
    • 4.3.2. Annual Cost of Therapy
    • 4.3.3. Treatment Usage Patterns

5. Diabetes Therapeutics Market to 2017-Therapeutic Landscape

  • 5.1. Type 1 Diabetes Market
    • 5.1.1. Introduction
    • 5.1.2. Symptoms
    • 5.1.3. Treatment
    • 5.1.4. Unmet Needs
    • 5.1.5. Branded vs. Generic Market Share in the Type 1 Diabetes Market
    • 5.1.6. Revenue
    • 5.1.7. Annual Cost of Therapy (ACT)
    • 5.1.8. Treatment Flow Algorithm for Type 1 Diabetes
    • 5.1.9. Treatment Usage Patterns
    • 5.1.10. Drivers and Restraints for the Type 1 Diabetes Market
  • 5.2. Type 2 Diabetes Market
    • 5.2.1. Introduction
    • 5.2.2. Symptoms
    • 5.2.3. Treatment
    • 5.2.4. Unmet Needs
    • 5.2.5. Branded vs. Generic Market Share in the Type 2 Diabetes Market
    • 5.2.6. Revenue
    • 5.2.7. Annual Cost of Therapy
    • 5.2.8. Treatment Flow Algorithm for Type 2 Diabetes
    • 5.2.9. Treatment Usage Patterns
    • 5.2.10. Drivers and Restraints for the Type 2 Diabetes Market

6. Diabetes Therapeutics Market to 2017-Pipeline Analysis

  • 6.1. Introduction
    • 6.1.1. Research and Development Pipeline-Type 1 Diabetes
    • 6.1.2. Research and Development Pipeline-Type 2 Diabetes
  • 6.2. Innovations in Diabetes Treatment
    • 6.2.1. Insulin in Pills (Oral Delivery)
    • 6.2.2. Promising Treatments for Diabetic Retinopathy
    • 6.2.3. Biomarkers in Diabetes
    • 6.2.4. Combination Drugs are an Important Part of the Diabetes Pipeline
    • 6.2.5. Cellular Activation Therapy (CAT)
  • 6.3. Drug Delivery in Diabetes
    • 6.3.1. Factors Determining Preference for Drug Delivery
    • 6.3.2. Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable
    • 6.3.3. Innovation in Drug Delivery Systems
  • 6.4. Profiles of Promising Drugs in the Diabetes Market
    • 6.4.1. rhGAD65 (Diamyd)
    • 6.4.2. Bydureon
    • 6.4.3. DiaPep277
    • 6.4.4. Otelixizumab
    • 6.4.5. Alogliptin
    • 6.4.6. Oral-Lyn
    • 6.4.7. Dapagliflozin
    • 6.4.8. Canagliflozin
    • 6.4.9. MB07803

7. Diabetes Therapeutics Market to 2017-Competitive Landscape

  • 7.1. Diabetes Market Overview
    • 7.1.1. Human Insulin Products and Oral Antidiabetic Drugs like Actos Group (Actos and Actoplus Met) and Lantus Have Led Market Growth
  • 7.2. Market Share Analysis-Diabetes
    • 7.2.1. Market Share Analysis by Company-2010
    • 7.2.2. Market Share Analysis by Company-2017
  • 7.3. Market Share Analysis by Class for the Anti-Diabetic Drugs
    • 7.3.1. Market Share Analysis by Drug Class-2010
    • 7.3.2. Market Share Analysis by Drug Class-2017
  • 7.4. Competitive Profiling
    • 7.4.1. Novo Nordisk
    • 7.4.2. Sanofi
    • 7.4.3. Takeda
    • 7.4.4. Eli Lilly
    • 7.4.5. GlaxoSmithKline (GSK)
    • 7.4.6. Merck & Co Inc
    • 7.4.7. Amylin Pharmaceuticals

8. Diabetes Therapeutics Market to 2017-M&A Landscape

  • 8.1. Overview
  • 8.2. Mergers and Acquisitions (M&A)
    • 8.2.1. Strategic Consolidation
    • 8.2.2. M&A Deals by Value
    • 8.2.3. Major Mergers and Acquisitions
    • 8.2.4. M&A Deals by Geography
    • 8.2.5. M&A Deals by Indication
  • 8.3. Licensing Agreements
    • 8.3.1. Licensing by Geography
    • 8.3.2. Major Licensing Agreements
    • 8.3.3. Licensing Agreements by Indication
    • 8.3.4. Licensing Agreements by Value
  • 8.4. Co-Development
    • 8.4.1. Co-Development by Geography
    • 8.4.2. Major Co-Development Deals
    • 8.4.3. Co-Development by Indication
    • 8.4.4. Co-Development by Value

9. Diabetes Therapeutics Market to 2017-Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Research Methodology
    • 9.3.1. Coverage
    • 9.3.2. Secondary Research
    • 9.3.3. Primary Research
    • 9.3.4. Forecasts
    • 9.3.5. Expert Panel Validation
  • 9.4. Contact Us
  • 9.5. Disclaimer
  • 9.6. Sources

List of Tables

  • Table 1: Diabetes Therapeutics Market, Global, Revenue ($bn), 2003-2010
  • Table 2: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 3: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2010
  • Table 4: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 5: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2003-2010
  • Table 6: Diabetes Therapeutics Market, The US, Revenue ($bn), 2003-2010
  • Table 7: Diabetes Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 8: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2010
  • Table 9: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017
  • Table 10: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2003-2010
  • Table 11: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2017
  • Table 12: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue, $bn, 2003-2010
  • Table 13: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, $bn, 2010-2017
  • Table 14: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2010
  • Table 15: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2003-2010
  • Table 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010-2017
  • Table 18: Diabetes Therapeutics Market, Japan, Revenues ($bn), 2003-2010
  • Table 19: Diabetes Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017
  • Table 20: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2010
  • Table 21: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017
  • Table 22: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2003-2010
  • Table 23: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2017
  • Table 24: Diabetes Therapeutics Market, Type 1 Diabetes Market, Types of Insulin Regimen
  • Table 25: Type 1 Diabetes Market, Global, Revenues ($bn), 2003-2010
  • Table 26: Type 1 Diabetes Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 27: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2010
  • Table 28: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 29: Type 1 Diabetes Market, Global, Treatment Usage Patterns (millions), 2003-2010
  • Table 30: Type 1 Diabetes Market, Global, Treatment Usage Patterns (millions), 2010-2017
  • Table 31: Type 2 Diabetes Market, Global, Revenues ($bn), 2003-2010
  • Table 32: Type 2 Diabetes Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 33: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2010
  • Table 34: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 35: Type 2 Diabetes Market, Global, Treatment Usage Patterns (millions), 2003-2010
  • Table 36: Type 2 Diabetes Market, Global, Treatment Usage Patterns (millions), 2010-2017
  • Table 37: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Discovery, 2011
  • Table 38: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Pre-Clinical, 2011
  • Table 39: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2011
  • Table 40: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2011
  • Table 41: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2011
  • Table 42: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, NDA Filed, 2011
  • Table 43: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Discovery, 2011
  • Table 44: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, IND Filed, 2011
  • Table 45: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2011
  • Table 46: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2011
  • Table 47: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2011
  • Table 48: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, NDA Filed, 2011
  • Table 49: Diabetes Therapeutics Market, Factors Determining Preference of Drug Delivery in Diabetes
  • Table 50: Diabetes Therapeutics Market, Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable
  • Table 51: Diabetes Therapeutics Market, Novo Nordisk, Pipeline Products, 2011
  • Table 52: Diabetes Therapeutics Market, Sanofi, Pipeline Products, 2011
  • Table 53: Diabetes Therapeutics Market, Takeda, Pipeline Products, 2011
  • Table 54: Diabetes Therapeutics Market, Eli Lilly, Pipeline Products, 2011
  • Table 55: Diabetes Therapeutics Market, GSK, Pipeline Products, 2011
  • Table 56: Diabetes Therapeutics Market, Merck, Pipeline Products, 2011
  • Table 57: Diabetes Therapeutics Market, Amylin, Pipeline Products (%), 2010
  • Table 58: Diabetes Therapeutics Market, Global, Strategic Consolidation, 2004-2011
  • Table 59: Diabetes Therapeutics Market, Global, Number of M&A Deals by Value, 2004-2011
  • Table 60: Diabetes Therapeutics Market, Global, Mergers and Acquisitions, 2010-2011
  • Table 61: Diabetes Therapeutics Market, Global, Number of M&A Deals by Geography, 2004-2011
  • Table 62: Diabetes Therapeutics Market, Global, Number of M&A Deals by Indication, 2004-2011
  • Table 63: Diabetes Therapeutics Market, Global, Number of Licensing Agreements by Geography, 2004-2011
  • Table 64: Diabetes Therapeutics Market, Global, Licensing Agreements, 2010-2011
  • Table 65: Diabetes Therapeutics Market to 2017, Global, Number of Licensing Agreements by Indication, 2004-2011
  • Table 66: Diabetes Therapeutics Market to 2017, Number of Licensing Agreements by Value, Global, 2004-2011
  • Table 67: Diabetes Therapeutics Market to 2017, Global, Number of Co-Development Deals by Geography, 2004-2011
  • Table 68: Diabetes Therapeutics Market to 2017, Global, Co-Development Deals, 2010-2011
  • Table 69: Diabetes Therapeutics Market to 2017, Global, Co-Development by Indication, 2004-2011
  • Table 70: Diabetes Therapeutics Market to 2017, Global, Number of Co-Development Deals by Value, 2004-2011

List of Figures

  • Figure 1: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2017
  • Figure 2: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2017
  • Figure 3: Diabetes Therapeutics Market, Global, Treatment Usage Patterns, 2003-2017
  • Figure 4: Diabetes Therapeutics Market, Global, Prevalence Population, 2003-2017
  • Figure 5: Diabetes Therapeutics Market, Global, Treatment Seeking Population, 2003-2017
  • Figure 6: Diabetes Therapeutics Market, Global, Diagnosed Population, 2003-2017
  • Figure 7: Diabetes Therapeutics Market, Global, Prescription Population, 2003-2017
  • Figure 8: Diabetes Therapeutics Market, Global, Drivers and Restraints
  • Figure 9: Diabetes Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2010
  • Figure 10: Diabetes Therapeutics Market, The US, Revenue Forecasts, ($bn), 2003-2017
  • Figure 11: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2017
  • Figure 12: Diabetes Therapeutics Market, The US, Treatment Usage Patterns, 2003-2017
  • Figure 13: Diabetes Therapeutics Market, The US, Prevalence Population, 2003-2017
  • Figure 14: Diabetes Therapeutics Market, The US, Treatment Seeking Population, 2003-2017
  • Figure 15: Diabetes Therapeutics Market, The US, Diagnosed Population, 2003-2017
  • Figure 16: Diabetes Therapeutics Market, The US, Prescription Population, 2003-2017
  • Figure 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, $bn, 2003-2017
  • Figure 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2017
  • Figure 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, 2003-2017
  • Figure 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Prevalence Population, 2003-2017
  • Figure 21: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population, 2003-2017
  • Figure 22: Diabetes Therapeutics Market, Top Five Countries of Europe, Diagnosed Population, 2003-2017
  • Figure 23: Diabetes Therapeutics Market, Top Five Countries of Europe, Prescription Population, 2003-2017
  • Figure 24: Diabetes Therapeutics Market, Japan, Revenue Forecasts ($bn), 2003-2017
  • Figure 25: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2017
  • Figure 26: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns, 2003-2017
  • Figure 27: Diabetes Therapeutics Market, Japan, Prevalence Population, 2003-2017
  • Figure 28: Diabetes Therapeutics Market, Japan, Treatment Seeking Population, 2003-2017
  • Figure 29: Diabetes Therapeutics Market, Japan, Diagnosed Population, 2003-2017
  • Figure 30: Diabetes Therapeutics Market, Japan, Prescription Population, 2003-2017
  • Figure 31: Type 1 Diabetes Market, Global, Unmet Needs
  • Figure 32: Type 1 Diabetes Market, Global, Branded vs. Generic Market Share (%), 2010
  • Figure 33: Type 1 Diabetes Market, Global, Revenue Forecasts ($bn), 2003-2017
  • Figure 34: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2017
  • Figure 35: Type 1 Diabetes Market, Global, Treatment Flow Algorithm
  • Figure 36: Type 1 Diabetes Market, Global, Treatment Usage Patterns, 2003-2017
  • Figure 37: Type 1 Diabetes Market, Global, Prevalence Population, 2003-2017
  • Figure 38: Type 1 Diabetes Market, Global, Treatment Seeking Population, 2003-2017
  • Figure 39: Type 1 Diabetes Market, Global, Diagnosed Population, 2003-2017
  • Figure 40: Type 1 Diabetes Market, Global, Prescription Population, 2003-2017
  • Figure 41: Type 1 Diabetes Market, Global, Diabetes Market Drivers and Restraints
  • Figure 42: Type 2 Diabetes Market, Global, Unmet Needs
  • Figure 43: Type 2 Diabetes Market, Global, Branded vs Generic Market Share, 2010
  • Figure 44: Type 2 Diabetes Market, Global, Revenue Forecasts ($bn), 2003-2017
  • Figure 45: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2017
  • Figure 46: Type 2 Diabetes Market, Global, Treatment Flow Algorithm
  • Figure 47: Type 2 Diabetes Market, Global, Treatment Usage Patterns, 2003-2017
  • Figure 48: Type 2 Diabetes Market, Global, Prevalence Population, 2003-2017
  • Figure 49: Type 2 Diabetes Market, Global, Treatment Seeking Population, 2003-2017
  • Figure 50: Type 2 Diabetes Market, Global, Diagnosed Population, 2003-2017
  • Figure 51: Type 2 Diabetes Market, Global, Prescription Population, 2003-2017
  • Figure 52: Type 2 Diabetes Market, Global, Market Drivers and Restraints, 2010-2017
  • Figure 53: Diabetes Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011
  • Figure 54: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011
  • Figure 55: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011,
  • Figure 56: Diabetes Therapeutics Market, Global, Market Share by Company (%), 2010
  • Figure 57: Diabetes Therapeutics Market, Global, Market Share by Company (%), 2017
  • Figure 58: Diabetes Therapeutics Market, Global, Market Share by Drug Class (%), 2010
  • Figure 59: Diabetes Therapeutics Market, Global, Market Share by Drug Class (%), 2017
  • Figure 60: Diabetes Therapeutics Market, Novo Nordisk, Revenue by Segment (%), 2010
  • Figure 61: Diabetes Therapeutics Market, Novo Nordisk, Diabetes Revenue by Product (%), 2010
  • Figure 62: Diabetes Therapeutics Market, SWOT Analysis, Novo Nordisk
  • Figure 63: Diabetes Therapeutics Market, Sanofi, Revenue by Segment (%), 2010
  • Figure 64: Diabetes Therapeutics Market, Sanofi, Diabetes Revenue by Product (%), 2010
  • Figure 65: Diabetes Therapeutics Market, SWOT Analysis, Sanofi
  • Figure 66: Diabetes Therapeutics Market, Takeda, Revenue by Segment (%), 2010
  • Figure 67: Diabetes Therapeutics Market, SWOT Analysis, Takeda
  • Figure 68: Diabetes Therapeutics Market, Eli Lilly, Revenue by Segment (%), 2010
  • Figure 69: Diabetes Therapeutics Market, Eli Lilly, Diabetes Revenue by Product (%), 2010
  • Figure 70: Diabetes Therapeutics Market, SWOT Analysis, Eli Lilly
  • Figure 71: Diabetes Therapeutics Market, GSK, Revenue by Segment (%), 2010
  • Figure 72: Diabetes Therapeutics Market, SWOT Analysis, GSK
  • Figure 73: Diabetes Therapeutics Market, Merck, Revenue by Segment, 2010
  • Figure 74: Diabetes Therapeutics Market, SWOT Analysis, Merck
  • Figure 75: Diabetes Therapeutics Market, Amylin, Revenue by Segment (%), 2010
  • Figure 76: Diabetes Therapeutics Market, Amylin, Diabetes Revenue by Product (%), 2010
  • Figure 77: Diabetes Therapeutics Market, SWOT Analysis, Amylin
  • Figure 78: Diabetes Therapeutics Market, Global, Strategic Consolidation (%), 2004-2011
  • Figure 79: Diabetes Therapeutics Market, Global, M&A Deals by Value (%), 2004-2011
  • Figure 80: Diabetes Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2011
  • Figure 81: Diabetes Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2011
  • Figure 82: Diabetes Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011
  • Figure 83: Diabetes Therapeutics Market, Global, Licensing Agreements by Indication (%), 2004-2011
  • Figure 84: Diabetes Therapeutics Market to 2017, Global, Licensing Agreements by Value (%), 2004-2011
  • Figure 85: Diabetes Therapeutics Market to 2017, Global, Co-Development by Geography (%), 2004-2011
  • Figure 86: Diabetes Therapeutics Market to 2017, Global, Co-Development by Indication (%), 2004-2011
  • Figure 87: Diabetes Therapeutics Market to 2017, Global, Co-Development Deals by Value (%), 2004-2011
  • Figure 88: Diabetes Therapeutics Market, GBI Research Market Forecasting Model
Back to Top